Barclays
CMPX icon

Barclays’s Compass Therapeutics CMPX Stock Holding History

Barclays’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-207,100
Closed -$1.1M – 5383
2026
Q1 		$1.1M Buy
+207,100
New +$1.2M ﹤0.01% 2704

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Barclays's CMPX Position: Q2 2026 in Review

Barclays reduced its Compass Therapeutics (CMPX) stake by 94% in Q2 2026, selling an estimated $2.18M and leaving 50,397 shares worth $110K. The position accounts for ﹤0.01% of the portfolio, ranked #3991.

Barclays first reported a position in CMPX in Q3 2022 and has held it in 16 quarters since. The position peaked at $4.18M in Q1 2026. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Barclays held 50,397 shares of Compass Therapeutics worth $110K as of Q2 2026.
  • Barclays sold 739,644 Compass Therapeutics shares in Q2 2026, an estimated $2.18M.
  • Compass Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3991 holding.
  • Barclays first reported a position in Compass Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • Barclays's Compass Therapeutics position peaked at $4.18M in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.